Trials / Terminated
TerminatedNCT05689164
A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne Muscular Dystrophy.
Long-term Follow-up Safety and Efficacy Study in Participants With Duchenne Muscular Dystrophy Who Have Received Fordadistrogene Movaparvovec in a Preceding Clinical Study
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- Male
- Age
- 0 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to understand the safety and effects of an experimental gene therapy called fordadistrogene movaparvovec. We are seeking participants from previous Pfizer interventional studies. We will follow participants' experience in this study for 10 years after the end of their previous study. Participants will have 1 annual onsite visit and a few annual remote visits. The exact number of remote visits will be decided by their study doctor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | fordadistrogene movaparvovec | gene therapy administered in a previous study. |
Timeline
- Start date
- 2023-03-13
- Primary completion
- 2025-09-24
- Completion
- 2025-09-24
- First posted
- 2023-01-19
- Last updated
- 2025-10-21
Locations
12 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05689164. Inclusion in this directory is not an endorsement.